CLDX · Celldex Therapeutics, Inc. · Insider Trading

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

As of June 18, 2024, the option is fully vested.

As of June 19, 2023, the option is fully vested.

On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

As of June 13, 2022, the option is fully vested.

Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

As of June 13, 2022, the option is fully vested.

25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

As of June 18, 2024, the option is fully vested.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Includes 269 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Such option vests in three equal annual installments beginning June 5, 2026.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.